VALN News and Press, Valneva SE From 02/14/23

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) said it completed enrollment and vaccination for a phase 3 trial of its single-shot chikungunya vaccine VLA1553 in adolescents. First results of the trial, dubbed  VLA1553-321, are expected mid-2023. The trial was conduct...

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) said it completed a rolling submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval of its single-shot chikungunya vaccine VLA1553 in people aged 18 years and above. The Biologics License Applic...

Shares of France-based biotech Valneva SE ( NASDAQ: VALN ) trended lower in European trading after France's public health body Haute Autorité de santé (HAS) advised against the use of the company's COVID-19 vaccine as part of a broader immunization drive. However, the HAS re...

Valneva SE (VALN) Q3 2022 Earnings Conference Call November 10, 2022 9:00 AM ET Company Participants Thomas Lingelbach – President and Chief Executive Officer Peter Buhler – Chief Financial Officer Conference Call Participants Maury Raycroft...

The following slide deck was published by Valneva SE in conjunction with their 2022 Q3 earnings call. For further details see: Valneva SE 2022 Q3 - Results - Earnings Call Presentation

Valneva press release ( NASDAQ: VALN ): Q3 Cash and cash equivalents of €261.0M at the end of September 2022 Revenue of €249.9M (+258.0% Y/Y). Valneva reiterates expected total revenues of €340 million to €360 million. Product sales...

Valneva ( NASDAQ: VALN ) ( OTCPK:INRLF ) upsized an offering to raise ~€102.9M (~$99.9M) from the previously expected $40M due to excess demand. The French vaccine maker is pricing of 21M ordinary shares in a global offering to certain inve...

Valneva SE ( NASDAQ: VALN ) to issue and sell ~$40M of its ordinary shares in a global offering. Offering is comprised of (i) a public offering of its ADSs, each representing two ordinary shares, in the US and (ii) a concurrent private placement of its shares in ...

French biotech Valneva SE ( NASDAQ: VALN ) announced Monday that the company is in discussions with a partner to secure funding to develop a second-generation COVID-19 vaccine. Previously, the biotech had said it would invest further in the second-generation vaccine if fun...

French biotech Valneva ( NASDAQ: VALN ) on Friday said it had agreed to terminate its COVID-19 vaccine drug substance manufacturing agreement with contract development organization IDT Biologika following the suspension of the manufacturing of the shot. The European Commissi...